The Nile Company for Pharmaceuticals and Chemical Industries Price Chart
The Nile Company for Pharmaceuticals and Chemical Industries EGS38331C012.CA Financial and Trading Overview
Contents
- The Nile Company for Pharmaceuticals and Chemical Industries Price Chart
- The Nile Company for Pharmaceuticals and Chemical Industries EGS38331C012.CA Financial and Trading Overview
- Valuation Measures
- Trading Information
- Financial Highlights
- Profile of The Nile Company for Pharmaceuticals and Chemical Industries
- Q&A For The Nile Company for Pharmaceuticals and Chemical Industries Stock
The Nile Company for Pharmaceuticals and Chemical Industries stock price | 80.22 |
Previous Close | 41.04 |
Open | 41.04 |
Bid | 39.02 x 0 |
Ask | 40.45 x 0 |
Day's Range | 39 - 39.61 |
52 Week Range | 39 - 39.61 |
Volume | 3K |
Avg. Volume | N/A |
Market Cap | N/A |
Beta (5Y Monthly) | N/A |
PE Ratio (TTM) | N/A |
EPS (TTM) | 0 |
Forward Dividend & Yield | N/A (N/A) |
Ex-Dividend Date | N/A |
1y Target Est | N/A |
EGS38331C012.CA Valuation Measures
Enterprise Value | N/A |
Trailing P/E | N/A |
Forward P/E | N/A |
PEG Ratio (5 yr expected) | N/A |
Price/Sales (ttm) | N/A |
Price/Book (mrq) | N/A |
Enterprise Value/Revenue | N/A |
Enterprise Value/EBITDA | N/A |
Trading Information
The Nile Company for Pharmaceuticals and Chemical Industries Stock Price History
Beta (5Y Monthly) | N/A |
52-Week Change | N/A |
S&P500 52-Week Change | N/A |
52 Week High | 39.61 |
52 Week Low | 39 |
50-Day Moving Average | N/A |
200-Day Moving Average | N/A |
EGS38331C012.CA Share Statistics
Avg. Volume (3 month) | N/A |
Avg. Daily Volume (10-Days) | N/A |
Shares Outstanding | N/A |
Float | N/A |
Short Ratio | N/A |
% Held by Insiders | N/A |
% Held by Institutions | N/A |
Shares Short | N/A |
Short % of Float | N/A |
Short % of Shares Outstanding | N/A |
Dividends & Splits
Trailing Annual Dividend Rate | N/A |
Trailing Annual Dividend Yield | N/A |
5 Year Average Dividend Yield | N/A |
Payout Ratio | N/A |
Last Split Factor | N/A |
Financial Highlights
Fiscal Year
Fiscal Year Ends | N/A |
Most Recent Quarter (mrq) | N/A |
Next Fiscal Year End | N/A |
Profitability
Profit Margin | N/A |
Operating Margin (ttm) | N/A |
Gross Margin | N/A |
EBITDA Margin | N/A |
Management Effectiveness
Return on Assets (ttm) | N/A |
Return on Equity (ttm) | N/A |
Income Statement
Revenue (ttm) | N/A |
Revenue Per Share (ttm) | N/A |
Quarterly Revenue Growth (yoy) | N/A |
Gross Profit (ttm) | N/A |
EBITDA | N/A |
Net Income Avi to Common (ttm) | N/A |
Diluted EPS (ttm) | N/A |
Quarterly Earnings Growth (yoy) | N/A |
Balance Sheet
Total Cash (mrq) | N/A |
Total Cash Per Share (mrq) | N/A |
Total Debt (mrq) | N/A |
Total Debt/Equity (mrq) | N/A |
Current Ratio (mrq) | N/A |
Book Value Per Share (mrq) | N/A |
Cash Flow Statement
Operating Cash Flow (ttm) | N/A |
Levered Free Cash Flow (ttm) | N/A |
Q&A For The Nile Company for Pharmaceuticals and Chemical Industries Stock
What is a current EGS38331C012.CA stock price?
The Nile Company for Pharmaceuticals and Chemical Industries EGS38331C012.CA stock price today per share is 80.22 .
How to purchase The Nile Company for Pharmaceuticals and Chemical Industries stock?
You can buy EGS38331C012.CA shares on the EGX exchange. Contact your financial advisor to select a broker.
What is the ticker symbol for The Nile Company for Pharmaceuticals and Chemical Industries?
The stock symbol or ticker of The Nile Company for Pharmaceuticals and Chemical Industries is EGS38331C012.CA.
How many shares does The Nile Company for Pharmaceuticals and Chemical Industries have in circulation?
The max supply of The Nile Company for Pharmaceuticals and Chemical Industries shares is 10.13M.
What is The Nile Company for Pharmaceuticals and Chemical Industries Price to Earnings Ratio (PE Ratio)?
The Nile Company for Pharmaceuticals and Chemical Industries PE Ratio is now.
What was The Nile Company for Pharmaceuticals and Chemical Industries earnings per share over the trailing 12 months (TTM)?
The Nile Company for Pharmaceuticals and Chemical Industries EPS is 0 over the trailing 12 months.